**Background**
The p38 mitogen-activated protein kinase (MAPK) pathway plays a critical role in the regulation of cellular responses to various external stimuli, including inflammatory cytokines, osmotic stress, and ultraviolet radiation. In particular, p38 MAPK is essential for the production of pro-inflammatory cytokines and the activation of several downstream enzymes involved in the inflammatory cascade. One such enzyme is the tumor necrosis factor $\alpha$-converting enzyme (TACE), also known as ADAM-17, which is responsible for the shedding of membrane-bound TNF-$\alpha$ into its soluble, active form. Dysregulation of the p38-TACE axis is often associated with chronic inflammatory diseases and autoimmune disorders. Therefore, developing highly specific inhibitors of p38 is of significant research interest for controlling excessive inflammation. In this context, we will introduce a p38 inhibitor – EO 1428.
**Definition**
EO 1428 is a highly specific inhibitor of p38 belonging to the aminobenzophenone class. According to the EO 1428 description, this compound is designed to target p38 MAPK to attenuate inflammatory responses.
**In Vitro Studies**
The EO 1428 biological activity has been demonstrated through its ability to modulate cytokine production and enzyme activity. In terms of chemical properties, the EO 1428 formula is $\text{C}_{20}\text{H}_{16}\text{BrClN}_2\text{O}$ with a molecular weight of 415.71. In vitro studies using human peripheral blood mononuclear cells (PBMC) showed that EO 1428 exhibits potent anti-inflammatory activity. Specifically, it inhibits the production of LPS-induced TNF-alpha with an $\text{IC}_{50}$ value of 4 nM and inhibits the production of LPS-induced IL-beta with an $\text{IC}_{50}$ value of 14 nM. Furthermore, EO 1428 (1 $\mu$M) markedly attenuates the up-regulation of tumor necrosis factor $\alpha$-converting enzyme (TACE) activity induced by LPS in primary human monocytes. These results indicate that the compound effectively disrupts the p38-mediated activation of TACE. In conclusion, EO 1428 is a potent and specific p38 inhibitor that effectively suppresses the production of pro-inflammatory cytokines in human PBMC.
Keywords
EO 1428, 321351-00-2, EO1428, EO-1428, p38 MAPK, specific p38 inhibitor, tumor necrosis factor α-converting enzyme, TACE, Inhibitor, inhibitor, inhibit
References